The U.S. Supreme Court has ruled in favor of Novartis in a landmark case concerning intellectual property rights and pharmaceutical patents. The decision allows the company to retain exclusive rights to its breakthrough cancer medication for an extended period, effectively blocking generic competitors from entering the market. Legal analysts say the ruling could have far-reaching implications for the pharmaceutical industry, reinforcing the strength of patent protections in the face of mounting pressure for affordable drug access. Patient advocacy groups have expressed concern over the impact on drug prices, while industry leaders applaud the decision as a win for innovation and research in